PanGenomic Health Subsidiary Announces First Sale of BDNF Biomarker Tests
17 November 2023 PanGenomic Health Inc. (“PanGenomic” or the “Company”) PanGenomic Health Subsidiary Announces First Sale of BDNF Biomarker Tests Vancouver, British Columbia, Canada, 17 November 2023 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that its subsidiary, MUJN Diagnostics Inc. (“MUJN Diagnostics”), has launched its BDNF (brain-derived neurotrophic factor) mental health biomarker health assessment service and completed its first sale of the point-of-care test marketed to health clinics in